MedTrace Logo

Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis

NCT03067753 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2017-03-01

No results posted yet for this study

Summary

Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis

Conditions

  • Cerebral Radiation Necrosis

Interventions

DRUG

Monosialoganglioside Ganglioside

Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.

DRUG

Methylprednisolone (Steroid Hormone)

Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.

DRUG

Prednisolone

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03067753 on ClinicalTrials.gov